Transplantation of Umbilical Cord Blood Cells for Patients with Neonatal Hypoxic-Ischemic Encephalopathy and Cerebral Palsy: From Preclinical Studies to Ongoing Clinical Trials
Pp. 225-254 (30)
Pedro M. Pimentel-Coelho, Paulo H. Rosado-de-Castro, Fernanda Gubert and Rosalia Mendez-Otero
Neonatal hypoxic-ischemic encephalopathy (HIE) is an important cause of longterm
neurological disability in children, being responsible for at least 14% of the cases of
cerebral palsy. Despite the moderate protection provided by therapeutic hypothermia, a
significant number of infants would still benefit from an adjuvant therapy. Since the first
report showing the beneficial effect of umbilical cord blood cells (UCBCs) transplantation
in a rat model of HIE in 2006, a growing number of studies have improved our
understanding of the mechanisms underlying the neuroprotective action of transplanted
cells in animal models of HIE, intrauterine hypoxia and neonatal stroke. The aim of this
book chapter is to summarize these findings and to discuss recent data from several clinical
trials and case reports that have evaluated the safety and feasibility of UCBCs therapy in
newborns with HIE and in children with cerebral palsy.
Astrocytes, brain repair, cell therapies, cerebral palsy, hematopoietic
stem cells, immunomodulation, microglia, mononuclear cells, neonatal
encephalopathy, neonatal hypoxia-ischemia, neuroprotection, regeneration, stem
cells, umbilical cord blood.
Instituto de Biofísica Carlos Chagas Filho, Universidade Federal do Rio Janeiro, Rio de Janeiro, Brazil.